ADOC.PA (Mkap €58 M) Cash €45 M --HOT Diabetes Pipeline (Seite 8)
eröffnet am 13.12.19 12:07:06 von
neuester Beitrag 18.04.24 13:08:47 von
neuester Beitrag 18.04.24 13:08:47 von
Beiträge: 75
ID: 1.316.924
ID: 1.316.924
Aufrufe heute: 0
Gesamt: 12.395
Gesamt: 12.395
Aktive User: 0
ISIN: FR0011184241 · WKN: A1JTC2
9,2150
EUR
+6,90 %
+0,5950 EUR
Letzter Kurs 13.05.24 Lang & Schwarz
Neuigkeiten
29.04.24 · Business Wire (engl.)  |
24.04.24 · Business Wire (engl.) |
12.04.24 · Business Wire (engl.) |
21.03.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,110 | +41,73 | |
| 3,0100 | +40,65 | |
| 2,5300 | +38,25 | |
| 2,5150 | +37,73 | |
| 4,3800 | +32,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,1200 | -18,64 | |
| 3,9900 | -19,39 | |
| 2,4100 | -20,98 | |
| 0,9900 | -27,21 | |
| 0,6162 | -56,61 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 62.154.257 von startvestor am 13.12.19 16:47:24Chart Euronext Paris:
Orderbuch paris:
https://live.euronext.com/en/product/equities/FR0011184241-X…
Chart:
https://www.comdirect.de/inf/aktien/detail/chart.html?POSITI…
Orderbuch paris:
https://live.euronext.com/en/product/equities/FR0011184241-X…
Chart:
https://www.comdirect.de/inf/aktien/detail/chart.html?POSITI…
Antwort auf Beitrag Nr.: 62.153.639 von Biohero am 13.12.19 16:02:37Interessant.
Antwort auf Beitrag Nr.: 62.151.863 von Biohero am 13.12.19 13:08:38Die bisherigen Daten von ADO-09 sind sehr vielversprechend wenn die sich in der neuen Studie weiter bestätigen dann wie gesagt gibts bestimmt einen saftigen Kurssprung . Verstehe nicht warum solche attraktive Biotechs in Frankreich so übest unterbewertet sind .
ADO09, a co-formulation of the amylin-analog pramlintide and the A21G human insulin analog, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes
https://www.adocia.com/wp-content/uploads/2019/09/PR_ADOCIA_…
“We are excited to share, through these promising initial clinical results, the potential of ADO09, our breakthrough coformulation of prandial insulin and pramlintide for the treatment of type 1 diabetes (T1D).” said Olivier Soula, Deputy General Manager and Director of R&D at Adocia.“With this coformulation, we aim to finally deliver on the promise of pramlintide for people with T1D, this therapeutic agent havingdemonstrated remarkable medical benefits, including better postprandial glycemic control and a constellation of other benefits that no other commercial treatment offers them today.”
Adocia develops faster, more physiologic insulins to improve the lives of people with diabetes. Eve-Marie, T1D, shares her daily life struggles and her hopes for improved life with diabetes.
https://www.adocia.com/france-3-auvergne-rhone-alpes-french-…
ADO09, a co-formulation of the amylin-analog pramlintide and the A21G human insulin analog, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes
https://www.adocia.com/wp-content/uploads/2019/09/PR_ADOCIA_…
“We are excited to share, through these promising initial clinical results, the potential of ADO09, our breakthrough coformulation of prandial insulin and pramlintide for the treatment of type 1 diabetes (T1D).” said Olivier Soula, Deputy General Manager and Director of R&D at Adocia.“With this coformulation, we aim to finally deliver on the promise of pramlintide for people with T1D, this therapeutic agent havingdemonstrated remarkable medical benefits, including better postprandial glycemic control and a constellation of other benefits that no other commercial treatment offers them today.”
Adocia develops faster, more physiologic insulins to improve the lives of people with diabetes. Eve-Marie, T1D, shares her daily life struggles and her hopes for improved life with diabetes.
https://www.adocia.com/france-3-auvergne-rhone-alpes-french-…
Antwort auf Beitrag Nr.: 62.151.272 von Biohero am 13.12.19 12:07:06Für den asiatischen Raum hat man bereits einen guten Partner gefunden , jetzt fehlt nur noch der richtige Partner für den Westen derkönnte jederzeit kommen .
Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China
https://www.adocia.com/wp-content/uploads/2018/04/180426-Ado…
•$50M up-front payment upon signing
•Up to $85M on milestones payments and expected double-digit royalties on products sales
Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China
https://www.adocia.com/wp-content/uploads/2018/04/180426-Ado…
•$50M up-front payment upon signing
•Up to $85M on milestones payments and expected double-digit royalties on products sales
Eine weitere sehr attraktive franz Perle mit kräftigen upside Potential . Kurz gefasst : Top Management - Niedrige Marktkap + dickes Cashpolster - Super Diabetes Pipeline -Extrem low float Aktie . Kaufgrund : wichtige Phase 1b Daten stehen vor jahresende an .
Die Aktie kommt von fast €100 hauptgrund für den Absturz war das Eli Lilly in 2017 die Partnerschaft aufgegeben hat mMn ziemlich übertrieben die reaktion .
In diesem Monat sollen noch wichtige Phase 1b Daten (ADO-09) kommen welche falls positiv bestimmt diese low float Aktie nach oben katapultieren könnten deshalb habe ich diese Woche ein paar gekauft .
We expect Adocia's portfolio to generate significant interest in business development, especially ADO-09 given its differentiation, which should be a catalyst for shares. Interest in ADO-09 should accelerate after additional data is reported in 4Q which should offer further proof of concept even though the study is being characterized as Phase 1b"
Adocia (ADOC)
Marktkap: €58 Million
Cash: €45 Million
Kurs: €8,35
Aktienanzahl: 6,94 M
Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes
https://www.adocia.com/wp-content/uploads/2019/06/ADO09-Outp…
Adocia is the sponsor of this study, which will be performed by Profil Neuss in Germany. Results of this study are expected in Q4 2019.
H.C. Wainwright analyst Douglas Tsao initiates coverage on Adocia (ADOC:FP) (OTC: ADOCY) with a Buy rating and $21 price target.
https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+H.C…
Gérard Soula ...898 463
BPIFrance Investissement SAS...784 357
KKR & Co. Inc...343 995
La Société Hospitalière d'Assurances Mutuelles SA...320 000
Rémi Soula...306 540
Olivier Soula...305 490
Groupe des Assurances du Crédit Mutuel SA...125 944
Norges Bank Investment Management...82 675
Talence Gestion SAS...63 533
Candriam Belgium SA...59 400
Die Aktie kommt von fast €100 hauptgrund für den Absturz war das Eli Lilly in 2017 die Partnerschaft aufgegeben hat mMn ziemlich übertrieben die reaktion .
In diesem Monat sollen noch wichtige Phase 1b Daten (ADO-09) kommen welche falls positiv bestimmt diese low float Aktie nach oben katapultieren könnten deshalb habe ich diese Woche ein paar gekauft .
We expect Adocia's portfolio to generate significant interest in business development, especially ADO-09 given its differentiation, which should be a catalyst for shares. Interest in ADO-09 should accelerate after additional data is reported in 4Q which should offer further proof of concept even though the study is being characterized as Phase 1b"
Adocia (ADOC)
Marktkap: €58 Million
Cash: €45 Million
Kurs: €8,35
Aktienanzahl: 6,94 M
Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes
https://www.adocia.com/wp-content/uploads/2019/06/ADO09-Outp…
Adocia is the sponsor of this study, which will be performed by Profil Neuss in Germany. Results of this study are expected in Q4 2019.
H.C. Wainwright analyst Douglas Tsao initiates coverage on Adocia (ADOC:FP) (OTC: ADOCY) with a Buy rating and $21 price target.
https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+H.C…
Gérard Soula ...898 463
BPIFrance Investissement SAS...784 357
KKR & Co. Inc...343 995
La Société Hospitalière d'Assurances Mutuelles SA...320 000
Rémi Soula...306 540
Olivier Soula...305 490
Groupe des Assurances du Crédit Mutuel SA...125 944
Norges Bank Investment Management...82 675
Talence Gestion SAS...63 533
Candriam Belgium SA...59 400
Durchsuchen
